Today's Date: October 2, 2023
NMG Pays Accrued Interests   •   Author Shares His Spiritual Journey to Building a Relationship with the Universal Christ   •   GoMacro® Celebrates Seventh Year of Partnership with the Keep A Breast Foundation   •   Faraday Future Announces Latest FF 91 2.0 Futurist Alliance Delivery   •   Accenture Acquires SIGNAL to Enhance its Integrated Marketing Capabilities in Japan   •   3 Takeaways from 3Bee CEO Niccolò Calandri's Letter for World Habitat Day 2023   •   OpenFold Drug Discovery AI Research Consortium Announces Funding of Large-Scale Protein Data Collection at Prof. Gabriel Rocklin   •   Canadian Cancer Society CIBC Run for the Cure brings hope and raises $14.5 million   •   RobotLAB Proudly Renews Longstanding NAO & Pepper Agreements With United Robotics Group   •   Elite Learning Celebrates World Mental Health Awareness Month with Continuing Education Courses at No Cost for Nurses   •   U.S. Women's Health Alliance Hosts Payer Provider Summit--Creating an Affordable Healthcare System that Saves Lives Through Stak   •   Stericycle Continues Partnership with the National Park Foundation to Support Habitats and Restore Wetlands in Yosemite National   •   Wirex Launches 2023 Rising Women in Crypto Power List   •   Shulman Rogers Launches Year Two of Local Black-Owned Business Program To Provide Free Legal Services For A Year   •   Trane Technologies to Acquire Connected Workplace and Enterprise Asset Management Leader Nuvolo   •   SLB, Aker Solutions and Subsea7 Announce Closing of OneSubsea Joint Venture   •   Children's Mental Health Matters, And It Can Be Fun, Too   •   LEADING OB/GYN PERFORMS 100th HIGH RISK PLACENTA ACCRETA CASE WITH NEW DEVICE TO MANAGE HEMORRHAGE   •   Great British Nuclear Selects the Westinghouse AP300™ SMR for the United Kingdom’s Newbuild Program   •   Children at Big Blue Marble Academy Eagerly Embrace Exciting Fall Activities
Bookmark and Share

BostonGene and Hokkaido University Hospital Collaborate to Develop Novel HER2 Protocols for Breast Cancer

WALTHAM, Mass. , September 19 /Businesswire/ - BostonGene today announced an agreement with Hokkaido University Hospital to drive the discovery, validation and implementation of a groundbreaking stratification protocol for HER2-positive breast cancer patients.

This press release features multimedia. View the full release here:

Located in Sapporo, Japan, Hokkaido University Hospital stands as one of the most prominent medical institutions in the country. Affiliated with Hokkaido University School of Medicine, the hospital offers both high-quality patient care and cutting-edge medical research with an international perspective. As an academic hospital, it is also committed to the mentorship and development of upcoming medical professionals through expansive training programs.

Conventional HER2-targeted antibodies, such as trastuzumab and pertuzumab, fall short in treating patients with HER2-low breast cancer. However, recent clinical trials have demonstrated that trastuzumab-deruxtecan, an antibody-drug conjugate targeting HER2, benefits these patients. Additional data are required to elucidate the best approach for identifying HER2-low patients likely to benefit from the novel therapy. A growing interest lies in the RNA-based method, which can simultaneously investigate the tumor microenvironment and HER2 expression levels. This collaboration aims to demonstrate the benefits of the methodology that interrogate the impacts of the tumor immune ecosystem on HER2-targeted therapy. In this study, BostonGene will apply its genomics pipeline to reveal key tumor drivers, including immune microenvironment properties and genomic biomarkers of response to diverse therapies. In addition, the BostonGene-developed unique and robust machine learning algorithm named Kassandra will digitally reconstruct the tissue tumor microenvironment and cellular composition to identify distinct cell populations. The joint research will be led by Professors Ichiro Kinoshita, MD, PhD at the Division of Clinical Cancer Genomics/Department of Medical Oncology and Masato Takahashi, MD, PhD at the Department of Breast Surgery, Hokkaido University Hospital.

“We are excited to enter into this partnership with BostonGene to fully understand the molecular profiles of our patients. BostonGene’s comprehensive solutions have the potential to deliver breakthrough discoveries and help us identify novel treatment approaches,” said Ichiro Kinoshita, MD, PhD.

“Breast cancer ranks as the primary cause of cancer in women across the country. Enhancing treatment outcomes remains a critical focus. Through the findings of this research, we aim to advance technologies that offer more precise medical care and minimize the recurrence of breast cancer in as many patients as possible,” said Masato Takahashi, MD, PhD.

“We're honored to partner with Hokkaido University providing our AI-based molecular and immune profiling to uncover treatable targets to personalize therapy for breast cancer patients,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “This collaboration supports our mission to equip doctors in finding the most effective treatment options for their patients.”

BostonGene, NEC Corporation and Japan Industrial Partners recently announced the formation of BostonGene Japan Inc., a Tokyo-based joint venture to advance personalized medicine and dramatically improve patient outcomes. The company will utilize BostonGene’s high-complexity molecular technology and advanced biocomputational algorithms to accelerate the development and validation of novel precision medicine approaches.

BostonGene will participate in the 82nd Annual Meeting of the Japanese Cancer Association (JCA) at Pacific Convention Plaza Yokohama from September 21 to September 23. Please contact Erin O’Reilly to learn more or to schedule a meeting.

About BostonGene Corporation

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and reduce overall cost of cancer care. BostonGene’s tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at

STORY TAGS: Photo/Multimedia, Contract/Agreement, Product/Service, Event, United States, Japan, North America, Asia Pacific, Research, Pharmaceutical, Oncology, Technology, Hospitals, University, Artificial Intelligence, Health Technology, Education, Clinical Trials, Science, Biotechnology, Health, Massachusetts,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News